Literature DB >> 33058403

Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?

Dimitrios Patoulias1, Christodoulos Papadopoulos2, Alexandra Katsimardou1, Maria Toumpourleka2, Michael Doumas1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33058403      PMCID： PMC8029775          DOI： 10.1111/jch.14079

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  8 in total

Review 1.  Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.

Authors:  Charalambos Vlachopoulos; Konstantinos Aznaouridis; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2010-03-30       Impact factor: 24.094

2.  Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?

Authors:  Theocharis Koufakis; Nikolaos Papanas; George Dimitriadis; Pantelis Zebekakis; Kalliopi Kotsa
Journal:  J Diabetes       Date:  2020-09-04       Impact factor: 4.006

3.  Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.

Authors:  Kristina Striepe; Agnes Jumar; Christian Ott; Marina V Karg; Markus P Schneider; Dennis Kannenkeril; Roland E Schmieder
Journal:  Circulation       Date:  2017-09-19       Impact factor: 29.690

4.  Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.

Authors:  Ignatios Ikonomidis; George Pavlidis; John Thymis; Dionysia Birba; Aimilianos Kalogeris; Foteini Kousathana; Aikaterini Kountouri; Konstantinos Balampanis; John Parissis; Ioanna Andreadou; Konstantinos Katogiannis; George Dimitriadis; Aristotelis Bamias; Efstathios Iliodromitis; Vaia Lambadiari
Journal:  J Am Heart Assoc       Date:  2020-04-24       Impact factor: 5.501

Review 5.  Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Konstantinos Stavropoulos; Ioanna Zografou; Michael Doumas; Asterios Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-14       Impact factor: 3.738

Review 6.  Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects.

Authors:  Yoav Ben-Shlomo; Melissa Spears; Chris Boustred; Margaret May; Simon G Anderson; Emelia J Benjamin; Pierre Boutouyrie; James Cameron; Chen-Huan Chen; J Kennedy Cruickshank; Shih-Jen Hwang; Edward G Lakatta; Stephane Laurent; João Maldonado; Gary F Mitchell; Samer S Najjar; Anne B Newman; Mitsuru Ohishi; Bruno Pannier; Telmo Pereira; Ramachandran S Vasan; Tomoki Shokawa; Kim Sutton-Tyrell; Francis Verbeke; Kang-Ling Wang; David J Webb; Tine Willum Hansen; Sophia Zoungas; Carmel M McEniery; John R Cockcroft; Ian B Wilkinson
Journal:  J Am Coll Cardiol       Date:  2013-11-13       Impact factor: 24.094

7.  Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.

Authors:  Anna Solini; Livia Giannini; Marta Seghieri; Edoardo Vitolo; Stefano Taddei; Lorenzo Ghiadoni; Rosa Maria Bruno
Journal:  Cardiovasc Diabetol       Date:  2017-10-23       Impact factor: 9.951

8.  Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.

Authors:  Kazuomi Kario; Kenta Okada; Mitsunobu Murata; Daisuke Suzuki; Kayo Yamagiwa; Yasuhisa Abe; Isao Usui; Norihiro Tsuchiya; Chie Iwashita; Noriko Harada; Yukie Okawara; Shun Ishibashi; Satoshi Hoshide
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-18       Impact factor: 3.738
  8 in total
  2 in total

1.  Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.

Authors:  Kazuomi Kario; Noriko Harada; Satoshi Hoshide
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-21       Impact factor: 3.738

2.  Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Ioanna Zografou; Alexandra Katsimardou; Asterios Karagiannis; Michael Doumas
Journal:  Medicina (Kaunas)       Date:  2022-08-27       Impact factor: 2.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.